| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 18 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 18 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 18 |
| 3 | ETOPOSIDE | 16 |
| 4 | METHOTREXATE SODIUM | 13 |
| 5 | METHOTREXATE | 12 |
| 6 | PREDNISOLONE | 10 |
| 7 | PREDNISOLONE ORAL | 10 |
| 8 | PREDNISOLONE ORAL SOLUTION | 10 |
| 9 | PREDNISONE | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PURIXAN | 1 | 0.0013 |
| 1 | VINBLASTINE SULFATE | 2 | 0.0010 |
| 2 | CLOFARABINE | 2 | 0.0009 |
| 3 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 4 | CARMUSTINE | 2 | 0.0004 |
| 5 | CERITINIB | 1 | 0.0004 |
| 6 | AXICABTAGENE CILOLEUCEL | 4 | 0.0004 |
| 7 | IFOSFAMIDE FOR INJECTION | 8 | 0.0004 |
| 8 | TRAMETINIB | 9 | 0.0004 |
| 9 | MITOXANTRONE HYDROCHLORIDE | 2 | 0.0003 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 25 |
| 1 | Alkylating Drug [EPC] | 24 |
| 2 | Topoisomerase Inhibitor [EPC] | 16 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 12 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 10 |
| 5 | Kinase Inhibitor [EPC] | 9 |
| 6 | Platinum-based Drug [EPC] | 8 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 6 |
| 8 | Thalidomide Analog [EPC] | 6 |
| 9 | Purine Antimetabolite [EPC] | 5 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Chimeric Antigen Receptor [EPC] | 4 | 0.0004 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 2 | Topoisomerase Inhibitor [EPC] | 16 | 0.0002 |
| 3 | Alkylating Drug [EPC] | 24 | 0.0001 |
| 4 | Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] | 1 | 0.0001 |
| 5 | Asparagine-specific Enzyme [EPC] | 1 | 0.0001 |
| 6 | Thrombopoietin Receptor Agonist [EPC] | 1 | 0.0001 |
| 7 | Purine Antimetabolite [EPC] | 5 | 0.0001 |
| 8 | BCL-2 Inhibitor [EPC] | 2 | 0.0000 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 10 | 0.0000 |